News

Primerica (PRI) reported $741.66 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 6.7%. EPS of $3.91 for the same period compares to $3.49 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $738.43 million, representing a surprise of +0.44%. The company delivered an EPS surprise of -4.87%, with the consensus EPS estimate being $4.11.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Primerica performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Average Client Asset Values: $99.5 billion compared to the $98.15 billion average estimate based on two analysts.
• Life Insurance Policies Issued: 86,587 versus the two-analyst average estimate of 88,619.
• Life-Licensed Sales Force, End of period: 142,855 versus the two-analyst average estimate of 142,011.
• Recruits: 110,710 versus 95,274 estimated by two analysts on average.
• Revenues- Net investment income: $37.81 million versus the four-analyst average estimate of $35.16 million. The reported number represents a year-over-year change of +21.7%.
• Revenues- Commissions and fees: $255.02 million versus $247.50 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.1% change.
• Revenues- Other, net: $17.42 million versus the four-analyst average estimate of $19.59 million. The reported number represents a year-over-year change of -10.7%.
• Revenues- Net premiums: $431.28 million versus $432.53 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.6% change.
• Adjusted Operating Revenues- Corporate and Other Distributed Products: $50.65 million versus the three-analyst average estimate of $48.12 million. The reported number represents a year-over-year change of +12.6%.
• Adjusted Operating Revenues- Investment and Savings Products: $243.72 million versus $226.63 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +15.9% change.
• Adjusted Operating Revenues- Term Life Insurance: $440.41 million versus the three-analyst average estimate of $439.62 million. The reported number represents a year-over-year change of +4.6%.
• Adjusted Operating Revenues- Senior Health: $6.88 million versus $18.13 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -63.2% change.

View all Key Company Metrics for Primerica here>>>

Shares of Primerica have returned -11.6% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Only $1 to See All Zacks' Buys and Sells

We're not kidding.

Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.

Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.